Form 8-K - Current report:
SEC Accession No. 0001641172-25-001708
Filing Date
2025-03-31
Accepted
2025-03-31 16:05:45
Documents
14
Period of Report
2025-03-28
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45199
2 ex3-1.htm EX-3.1 6275
  Complete submission text file 0001641172-25-001708.txt   230619

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE awh-20250328.xsd EX-101.SCH 3011
4 XBRL LABEL FILE awh-20250328_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE awh-20250328_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3988
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 25793174
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)